This Sounding Board announces a new FDA policy that the default requirement for FDA approvals will be one robust pivotal trial plus confirmatory evidence, rather than two trials.

Explore this issue of The New England Journal of Medicine (Vol. 394 No. 13).

This article has been retracted.

A 74-year-old man with myasthenia gravis was evaluated for dyspnea, proximal muscle weakness, hypoxemia, and a painful tongue ...

Health worker burnout, exacerbated by Covid-19, is not only about long hours. It’s about the fundamental disconnect between health workers and the mission to serve that motivates them.

Monoclonal Gammopathy of Undetermined Significance (N Engl J Med 2025;393:1315-1326). In Table 1 (page 1317), the third footnote (denoted by ‡) should have read, “Bone marrow aspiration can be defe ...

Explore this issue of The New England Journal of Medicine (Vol. 392 No. 22).

Author: The SODa-BIC Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials GroupAuthor Info & Affiliations In this pragmatic, adaptive, double-blind, randomized trial ...

This video will demonstrate how to perform a comprehensive pelvic examination, which includes an examination of the external genitalia, a Papanicolaou test, a bimanual examination, as well as a ...

To the Editor: Baxdrostat, an oral aldosterone antagonist, was shown by Flack et al. (Oct. 9 issue) to lead to a substantially lower seated systolic blood pressure in patients with uncontrolled or ...

A proposed reclassification of medical marijuana products as Schedule III drugs would address only two of the three key barriers to research on marijuana’s safety and effectiveness for various ...

Core elements of the pay-for-performance approach have inherent shortcomings. Achieving meaningful quality improvement at scale may require rethinking this paradigm.